Capsule Summary Slidesets

Share

Program Content

Activities

  • Allogenic Anti-BCMA CAR T-Cell in R/R MM
    First-in-Human Phase I UNIVERSAL Trial of Allogeneic CAR T-Cell Therapy With ALLO-715 (Anti-BCMA) and ALLO-647 (Anti-CD52) in Patients With R/R MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2020

  • CRB-402: bb21217 in R/R MM
    Updated Analysis of Phase I CRB-402: bb21217 Anti-BCMA CAR T-Cell Therapy in Patients With R/R MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2020

    Expires: December 10, 2021

  • PRIME: P-BCMA-101 in R/R MM
    PRIME Phase I/II Trial of P-BCMA-101: Novel CAR T-Cell Therapy in R/R Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 07, 2020

    Expires: December 06, 2021

  • DREAMM-2: Outcomes by Prior Tx
    Phase II DREAMM-2 Study of Belantamab Mafodotin in R/R MM: Outcomes by Number of Prior Therapies
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2020

    Expires: December 08, 2021

  • DREAMM-6: Belamaf + Vd in R/R MM
    Phase II DREAMM-6 Arm B: Preliminary Analysis of Belantamab Mafodotin + Bortezomib/Dexamethasone in R/R MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2020

    Expires: December 10, 2021

  • DREAMM-2: Ocular Safety
    DREAMM-2: Ocular Safety During Phase II Study of Belantamab Mafodotin in R/R MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2020

    Expires: December 13, 2021

  • CARTITUDE-1: Cilta-Cel in R/R MM
    CARTITUDE-1 Phase Ib/II Study of Ciltacabtagene Autoleucel: BCMA-Directed CAR T-Cell Therapy in Patients With R/R MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2020

  • MEDI2228: R/R MM
    BCMA-Targeted ADC MEDI2228: First-in-Human Phase I Study in Patients With R/R Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2020

    Expires: December 13, 2021

  • Teclistamab in R/R MM
    Phase I Trial: Updated Analysis of BCMA x CD3 Bispecific Antibody Teclistamab (JNJ-64007957) in Patients With R/R MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 08, 2020

  • Phase I AMG 701
    First-in-Human Phase I Study of AMG 701: Anti-BCMA Bispecific Antibody in Patients With R/R MM
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 07, 2020

  • MAIA Update: D-Rd vs Rd
    MAIA Updated Analysis: Phase III Study of D-Rd vs Rd for ASCT-Ineligible Newly Diagnosed MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2020

    Expires: December 16, 2021

  • Talquetamab in R/R MM
    First-in-Human Phase I Trial of GPCR5D x CD3 Bispecific Antibody Talquetamab in Patients With R/R MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2020

    Expires: December 10, 2021

  • REGN5458 in R/R MM
    First-in-Human Phase I Study of BCMA x CD3 Bispecific Antibody REGN5458 in Patients With R/R MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2020

    Expires: December 14, 2021

  • Cevostamab in R/R MM
    Cevostamab: Novel FcRH5 x CD3 Bispecific Antibody in Patients With R/R MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2020

  • APOLLO: SC Dara + Pd vs Pd
    Phase III APOLLO: Daratumumab SC + Pom/Dex vs Pom/Dex Alone in Patients With R/R MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 10, 2020

    Expires: December 09, 2021

  • GRIFFIN: DVRd vs VRd Maintenance Phase Update
    GRIFFIN Maintenance Phase Update: Daratumumab + VRd → Dara-R vs VRd → R Alone for ASCT-Eligible Patients With Newly Diagnosed MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2020

    Expires: December 08, 2021

  • TOURMALINE-MM2: IRd in ND MM
    TOURMALINE-MM2: Oral Ixazomib-Rd vs Placebo-Rd for ASCT-Ineligible Patients With Newly Diagnosed MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2020

    Expires: December 08, 2021

  • Iberdomide + Dd or Vd in R/R MM
    Phase I/II Trial of Iberdomide Plus Daratumumab/Dex or Bortezomib/Dex in R/R MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2020

  • ALGONQUIN Part 1
    ALGONQUIN Part 1: Phase I Trial of Belantamab Mafodotin With Pomalidomide/Dexamethasone in Patients With R/R Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 08, 2020

    Expires: December 07, 2021

  • STOMP: Selinexor + Pom/Dex
    STOMP Phase I/II Trial: Selinexor/Pomalidomide/Dexamethasone in R/R MM After ≥ 2 Previous Therapies
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 10, 2020

    Expires: December 09, 2021

Provided by

ProCE Banner

Supporters

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology